Gemita 1gm Injection

About Gemita 1gm Injection

Gemita 1gm Injection contains Gemcitabine, a chemotherapy medication used in the treatment of several cancers, including bladder cancer, breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer. It works by interfering with the growth and division of cancer cells, helping to slow or stop the progression of the disease. Before starting treatment, patients should inform their healthcare provider about any history of heart disease, liver disorders, kidney problems, recent radiotherapy, or recent vaccinations, as these conditions may require special monitoring. Gemita 1gm Injection is generally not recommended for children and adolescents under 18 years of age. During treatment, regular blood tests are performed to monitor blood cell counts, liver function, and kidney function to help ensure safe and effective therapy. Patients should use effective contraception during treatment and for at least six months after the final dose to prevent pregnancy-related risks. As Gemcitabine may affect male fertility, men are advised not to father a child during treatment and for six months after completing therapy. Patients following a sodium-restricted diet should also inform their doctor, as this medication contains sodium. Immediate medical attention should be sought if symptoms such as shortness of breath, wheezing, unusual bleeding, changes in urine output or color, or persistent upper abdominal pain occur while receiving Gemita 1gm Injection. Regular medical supervision is important to manage side effects and optimize treatment outcomes.